# Japanese oncology guidelines (JSMO, JSCO and organ societies)

Source: https://onco.cc/collections/jsmo-jsco-guidelines/  
OnCo record `jsmo-jsco-guidelines` (Collection). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The JSMO and JSCO guidelines are Japan's oncology guidelines, especially strong for gastric, oesophageal, liver and biliary cancers where Japanese trials set global standards (D2 gastrectomy, S-1, endoscopic resection), and for Japan's own approvals through PMDA.

## Summary

Japanese organ societies publish some of the most detailed surgical and endoscopic guidelines in oncology (JGCA gastric cancer treatment guidelines, 6th edition 2021; Japan Esophageal Society; JSH hepatocellular carcinoma), reflecting trials such as JCOG9501, ACTS-GC, SPIRITS and JCOG1109. Drug availability differs (S-1, nedaplatin, TAS-102 origin), and PMDA approvals sometimes precede FDA (e.g. entrectinib, nivolumab for gastric cancer, cabozantinib-nivolumab). JSMO's clinical guidance on comprehensive genomic profiling underpins Japan's national reimbursement of CGP panels (2019).

## Fields

- Kind: Collection
- Last checked: 2026-09-08
- Tags: gap-fill; guidelines
- URL: https://www.jsmo.or.jp/en/
- Holds: Japanese Society of Medical Oncology and Japan Society of Clinical Oncology guidelines; organ-specific societies (JGCA gastric, JSHBPS, JLCS lung, JBCS breast) publish detailed guidelines many translated into English; the JSMO/JSCO/JCA joint guideline on tumour-agnostic testing.
- Licence: Society terms

## Sources

- JSMO: https://www.jsmo.or.jp/en/
- JGCA guidelines 2021 (Gastric Cancer): https://doi.org/10.1007/s10120-022-01331-8

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- technologies: [Comprehensive genomic profiling](https://onco.cc/technologies/cgp/), [Endoscopic resection (EMR / ESD)](https://onco.cc/technologies/endoscopic-resection/)
- companies: [Japan Clinical Oncology Group (JCOG)](https://onco.cc/companies/jcog/)
- institutions: [Cancer Institute Hospital of JFCR](https://onco.cc/institutions/jfcr/), [Japanese Society of Medical Oncology](https://onco.cc/institutions/jsmo/), [Kyoto University Hospital](https://onco.cc/institutions/kyoto-university-hospital/), [National Cancer Center Hospital](https://onco.cc/institutions/ncc-japan/)
- journals: [International journal of clinical oncology](https://onco.cc/journals/international-journal-of-clinical-oncology/)

---
JSON: https://onco.cc/api/v1/entities/jsmo-jsco-guidelines.json